CVC's $400M Secondary Sale of HealthCare Global to KKR, Explained

One private equity firm sold India's largest cancer hospital chain to another. CVC bought HealthCare Global at ₹130 a share in 2020 and handed it to KKR at ₹445 five years later, a $400M deal and a ~3.4x return. No founder cashed out, no business changed what it does. Only the owner did.

That is the whole story in one sentence, and it is also the reason this deal is worth reading closely. Every other teardown in this newsletter has involved a strategic buyer absorbing a target, or a multinational parent exiting a listed Indian subsidiary. This one is neither. It is a fund-to-fund handover: CVC's Aceso vehicle, which built its stake in HealthCare Global (HCG) during the depths of the COVID-19 pandemic, sold control to KKR at a price that valued the platform roughly 3.4 times higher than what CVC paid in. The hospitals kept treating patients, the founder kept his office, and the only thing that moved was which fund's name sat on the shareholder register.

The Setup, the Move, and the Point

• The setup. In June 2020, at the height of pandemic uncertainty, CVC's Aceso Company Pte Ltd invested roughly ₹384 Cr in HCG through a share subscription at ₹130/share, plus a further ₹129 Cr through warrants — a rescue-priced entry into a hospital chain that needed capital and got it from a fund willing to underwrite oncology care through a public-health crisis. By September 2020, Aceso's stake had grown to 49.99%, and it built toward majority control over the years that followed.
• The move. On February 23, 2025, KKR signed a definitive agreement to buy up to 54% of HCG from CVC's Aceso vehicle at ₹445/share, a deal valuing the transaction at roughly $400M. Because HCG is listed, the purchase triggered a mandatory open offer to public shareholders for a further 26%, priced under SEBI's takeover formula at ₹504.41/share — meaning KKR's eventual stake could land anywhere between 54% and 77% depending on how many public shareholders tendered.
• The point. This is what a clean secondary exit looks like in Indian healthcare: no restructuring drama, no founder walking away with a check, no change to what the business does day to day. CVC bought scarcity — India's only private oncology platform operating at real scale — held it through a growth phase, and sold that same scarcity to a buyer with a bigger balance sheet and an existing hospital platform to bolt it onto.

The headline number that makes this a teardown worth reading: the exit price and the public open-offer price are not the same number, and that gap is not an accident. Sources: CVC media statement, KKR/HCG joint announcement, BSE filings.

What HealthCare Global Actually Is

Founded in 1989 by Dr B.S. Ajaikumar, HealthCare Global Enterprises operates 25 cancer care centres across 19 cities in India, with roughly 2,500 beds, 100 operating theatres, and 40 linear accelerator (LINAC) machines for radiation therapy. It is, by scale, the only private oncology-focused hospital platform operating at this size anywhere in India. Most general hospital chains treat cancer as one department among many; HCG built its entire footprint around it instead. That specialisation is the asset. A generalist hospital group can add oncology capacity; building 25 centres' worth of specialist radiation equipment, trained oncologists, and referral relationships from scratch cannot be done quickly, which is exactly why a platform like this trades at a premium to a generic hospital chain of similar revenue.

Five years, one price that tripled and change. Sources: CVC statement, KKR/HCG joint press release, Businesswire, BSE/SEBI filings.

The Return, and Why the Math Is Cleaner Than It Looks

In plain terms, a secondary sale: one financial sponsor selling its stake to another financial sponsor, rather than to a strategic operator or back to the company itself. The business, its management, and its operations are unaffected in the near term — what changes is which fund's capital and which fund's hold-period clock now sits behind the ownership.

• ₹130 to ₹445 is a real number, and it is not adjusted for anything. CVC's original entry combined a ₹130/share equity subscription with a separate warrant subscription, so its true blended cost basis was almost certainly higher than ₹130 alone once the warrants are folded in. The ~3.4x figure quoted publicly compares headline share prices, not a fully loaded return net of warrant dilution and any capital CVC deployed along the way — treat it as the right order of magnitude, not a precise IRR.
• Five years at ~3.4x works out to roughly a 28% annualised return, using the simple compounding math (3.4 to the power of 1/5, minus one). That sits comfortably inside — arguably at the strong end of — what a control-stake healthcare platform investment is expected to deliver over a five-year hold, especially one entered at a stressed, pandemic-era price.
• The entry price was depressed by the moment, not by the business. June 2020 was a period of acute uncertainty for hospital operators: elective procedures were down, capital markets were closed to weaker credits, and CVC was one of the few funds willing to underwrite a specialist oncology platform through that window. Part of the 3.4x is genuine value creation; part of it is simply the spread between a crisis-priced entry and a normalised exit.

Two Prices, Two Mechanisms: The Exit Price vs. the Open-Offer Price

In plain terms, the open-offer price: under SEBI's takeover code, when an acquirer buys control of a listed Indian company, it must offer public shareholders an exit for at least 26% of the company, at a price set by a formula anchored to trading data around the announcement date. It is a regulatory floor, not a negotiation, and it is calculated independently of whatever price the controlling shareholder actually negotiated.

Here the two numbers point in an unusual direction relative to most deals this newsletter has covered. In several prior teardowns — JSW's purchase of Akzo Nobel India, or ChrysCapital's buyout of Novartis India — the market re-rated the stock upward immediately after announcement, leaving the formula-based open-offer price stranded below where the stock actually traded, and public shareholders declined to tender. In this deal, the open-offer price of ₹504.41/share was set above the ₹445/share KKR paid CVC for control. That is not a contradiction — the two prices are calculated by entirely different mechanisms, one negotiated bilaterally between two sophisticated funds and one set mechanically off historic trading data — but it is a useful reminder that “the deal price” and “the open-offer price” answer two different questions and should never be treated as the same number when you are modelling a takeover.

The negotiated price and the regulatory floor, moving in opposite directions from most of this newsletter's prior deals. Sources: KKR/HCG joint announcement, SEBI open-offer filings.

Why the Founder Didn't Sell

The detail that separates this deal from almost every other ownership change covered in this newsletter: the person who built the business is still in the building. Dr B.S. Ajaikumar founded HCG in 1989 and ran it for over three decades before CVC's 2020 investment diluted his personal stake to a minority position. In this transaction, he moves to Non-Executive Chairman, staying focused on clinical and research work rather than day-to-day operations — but he did not sell out, because by 2025 the shares being transacted were CVC's, not his.

That is the mechanical explanation for why “no founder cashed out” here: once a fund holds majority control, the founder's remaining stake is a minority position that simply isn't large enough to be the subject of a control transaction. The more interesting question is why KKR wanted him to stay at all, and the answer is scarcity of a different kind — clinical reputation and physician relationships built over 35 years don't transfer with a share purchase agreement the way a hospital building does.

Why This Fits Inside KKR's Existing India Healthcare Bet

KKR was not building a healthcare platform in India from zero. It already holds a stake in Max Healthcare, one of the country's largest hospital networks, which is broad and multi-specialty by design. HCG is the opposite shape: narrow, deep, and built entirely around oncology. Bolting a specialist cancer-care platform onto a generalist network is a different move from buying a second general hospital chain — it adds a service line Max doesn't have at HCG's scale, rather than adding more of what KKR's existing platform already does. Whether the two platforms are formally integrated or run as separate investments is a decision for KKR's portfolio construction, not something this deal's public filings settle — but the strategic logic of pairing a specialist asset with a generalist one is consistent with how consolidators in other sectors covered in this newsletter have behaved.

Three Things This Deal Confirms About Indian Healthcare PE

• For funds nearing the end of a hold period, a sponsor-to-sponsor sale is a clean exit. No new operator due diligence on whether a strategic buyer's culture fits, no employee integration risk, no customer-facing disruption. CVC sold to a buyer who already understands healthcare platform economics, which likely compressed the time between agreement and close relative to a strategic sale.
• For platform builders, category leadership commands a premium that a generic asset of the same revenue would not get. HCG's scarcity value — the only private oncology platform at real scale in India — is doing real work in that 3.4x, separate from whatever organic growth the business delivered over five years.
• For public shareholders in any Indian takeover, the open-offer price is a formula output, not a market read. This deal happened to price the open offer above the control price; others in this newsletter have shown the opposite. Either way, the lesson is the same: read the open-offer mechanics on their own terms, and don't assume they track the negotiated deal price in either direction.

Ownership changed hands twice in five years; the hospitals never closed a single day. Sources: BSE filings, CVC and KKR statements.

Read this before you evaluate a secondary sale in Indian healthcare. Three questions matter more than the headline multiple: was the entry price depressed by a moment (a crisis, a sector scare) rather than by the business itself; does the asset have a scarcity characteristic — category leadership, a licence, a specialist capability — that a generic competitor of the same size couldn't replicate quickly; and does the incoming buyer already have a platform to bolt the asset onto, or is it starting cold. HCG scores well on the first two and, given KKR's existing Max Healthcare stake, plausibly on the third as well. Not investment advice.